WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Tuesday, February 23, 2016

Consortium of drug companies to speed up Parkinson's research

The seven pharmaceutical companies involved in the consortium believe working together will drive down the costs of clinical trials and make them more effective.

By Stephen Feller    Feb. 23, 2016


Research into brain diseases can be costly and includes many dead-ends, but seven companies are banding together on investment and research in an effort to bring the first new drugs for Parkinson's disease in more than a decade to the market, the organization Parkinson's UK announced. Photo by Mrs_ya/Shutterstock
LONDON

Seven major pharmaceutical companies in Britain are joining forces, and funding, in an attempt to drive down the costs of clinical trials for Parkinson's disease treatments, and increase the efficacy of drugs they investigate.
The AbbVie, AstraZeneca, Biogen, Eli Lilly and Company, Merck Sharp and Dohme, Pfizer, and UCB announced they will be working with Parkinson's UK and the Critical Path Institute to improve research and care for Parkinson's patients.The increasing cost of bringing drugs from research to market has bogged down the process, which is why the two groups have worked to motivate companies to come together.

"There is a strong realization from the industry that collaboration among industry, academia, and worldwide regulatory agencies, along with the sharing of data, has the potential to create a more efficient development process," Dr. Diane Stephenson, executive director for the consortium, said in a press release."This recognition is evidenced by the fast pace at which members of this new consortium have joined."

The consortium took shape in October 2015 with the intention of linking researchers, drug companies and regulators to speed up the process and find ways to increase the number of participants in trials. About 70 percent of patients are willing to participate in drug trials, but only 24 percent have done so according to Parkinson's UK

The effort will be based at the Critical Path Institute in Arizona, with more than $1 million expected to be spent during the next three years, the consortium says in mission statement."Investing in clinical trials for brain disorders currently carries a high cost and high risk of failure," 

Dr. Arthur Roach, director of research at Parkinson's UK, said. "We see the consortium as a crucial part of strategies to develop new treatments that work at the earliest stage of the condition, with the goal of slowing its progression, and eventually finding a cure."


http://www.upi.com/Health_News/2016/02/23/Consortium-of-drug-companies-to-speed-up-Parkinsons-research/3511456241523/?spt=sec&or=hn

No comments:

Post a Comment